Current and future immunotherapeutic approaches in pancreatic cancer treatment

The Role of Innate and Adaptive Immune Cells in the Pathogenesis and Development of the Inflammatory Response in Ulcerative Colitis

A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.

IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue